Mitsuro Kanda1, Yun-Suhk Suh2, Do Joong Park2, Chie Tanaka1, Sang-Hoon Ahn2, Seong-Ho Kong2, Hyuk-Joon Lee2,3, Daisuke Kobayashi1, Michitaka Fujiwara1, Hideaki Shimada4, BeLong Cho5,6, Kenta Murotani7, Hyung-Ho Kim2, Han-Kwang Yang2,3, Yasuhiro Kodera8. 1. Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. 2. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 3. Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. 4. Department of Gastroenterological Surgery, Graduate School of Medicine, Toho University, Ota City, Japan. 5. Department of Family Medicine, Center for Health Promotion and Optimal Aging, Seoul National University College of Medicine and Hospital, Seoul, Korea. 6. Institute On Aging, Seoul National University College of Medicine, Seoul, Korea. 7. Biostatistics Center, Graduate School of Medicine, Kurume University, Kurume, Japan. 8. Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. ykodera@med.nagoya-u.ac.jp.
Abstract
BACKGROUND: Development of high-performance serum biomarkers will likely improve treatment outcomes of patients with gastric cancer (GC). We previously identified the candidate serum markers, anosmin 1 (ANOS1), dihydropyrimidinase-like 3 (DPYSL3), and melanoma-associated antigen D2 (MAGE-D2) and evaluated their clinical significance through a single-center retrospective analysis. Here we conducted a prospective multicenter observational study aimed at validating the diagnostic performance of these potential markers. METHODS: We analyzed serum levels before and after surgery of the three potential biomarkers in patients with GC and healthy volunteers. Quantification of serum and GC tissue levels was performed using an ELISA. RESULTS: Area under the curve (AUC) values that discriminated patients with GC from healthy controls were - 0.7058, 0.6188, and 0.5031 for ANOS1, DPYSL3, and MAGED2, respectively. The sensitivity and specificity of the ANOS1 assay were 0.36 and 0.85, respectively. The AUC value of ANOS1 that discriminated patients with stage I GC from healthy controls was 0.7131. Serum ANOS1 levels were significantly elevated in patients with stage I GC compared with those of healthy controls (median 1179 ng/ml and 461 ng/ml, respectively, P < 0.0001) and decreased after resection of primary GC lesions (P < 0.0001). The combination of serum ANOS1 and DPYSL3 levels increased the AUC value that discriminated patients with GC from healthy controls. Serum levels of ANOS1 did not significantly correlate with those of carcinoembryonic antigen, carbohydrate antigen 19-9, or other markers of inflammation. CONCLUSIONS: Serum levels of ANOS1 may serve as a useful diagnostic tool for managing GC.
BACKGROUND: Development of high-performance serum biomarkers will likely improve treatment outcomes of patients with gastric cancer (GC). We previously identified the candidate serum markers, anosmin 1 (ANOS1), dihydropyrimidinase-like 3 (DPYSL3), and melanoma-associated antigen D2 (MAGE-D2) and evaluated their clinical significance through a single-center retrospective analysis. Here we conducted a prospective multicenter observational study aimed at validating the diagnostic performance of these potential markers. METHODS: We analyzed serum levels before and after surgery of the three potential biomarkers in patients with GC and healthy volunteers. Quantification of serum and GC tissue levels was performed using an ELISA. RESULTS: Area under the curve (AUC) values that discriminated patients with GC from healthy controls were - 0.7058, 0.6188, and 0.5031 for ANOS1, DPYSL3, and MAGED2, respectively. The sensitivity and specificity of the ANOS1 assay were 0.36 and 0.85, respectively. The AUC value of ANOS1 that discriminated patients with stage I GC from healthy controls was 0.7131. Serum ANOS1 levels were significantly elevated in patients with stage I GC compared with those of healthy controls (median 1179 ng/ml and 461 ng/ml, respectively, P < 0.0001) and decreased after resection of primary GC lesions (P < 0.0001). The combination of serum ANOS1 and DPYSL3 levels increased the AUC value that discriminated patients with GC from healthy controls. Serum levels of ANOS1 did not significantly correlate with those of carcinoembryonic antigen, carbohydrate antigen 19-9, or other markers of inflammation. CONCLUSIONS: Serum levels of ANOS1 may serve as a useful diagnostic tool for managing GC.
Authors: Verónica Murcia-Belmonte; Pedro F Esteban; José Martínez-Hernández; Agnès Gruart; Rafael Luján; José María Delgado-García; Fernando de Castro Journal: Brain Struct Funct Date: 2015-02-08 Impact factor: 3.270
Authors: Do Joong Park; An Na Seo; Changhwan Yoon; Geoffrey Y Ku; Daniel G Coit; Vivian E Strong; Yun-Suhk Suh; Hye Seung Lee; Han-Kwang Yang; Hyung-Ho Kim; Sam S Yoon Journal: Ann Surg Oncol Date: 2015-08-11 Impact factor: 5.344
Authors: A Marcell Szász; András Lánczky; Ádám Nagy; Susann Förster; Kim Hark; Jeffrey E Green; Alex Boussioutas; Rita Busuttil; András Szabó; Balázs Győrffy Journal: Oncotarget Date: 2016-08-02
Authors: Liang Wenquan; Liu Yuhua; Cui Jianxin; Xi Hongqing; Zhang Kecheng; Li Jiyang; Gao Yunhe; Liu Yi; Zhang Wang; Li Shaoqing; Lu Yixun; Qiao Shen; Xue Wanguo; Qiao Zhi; Chen Lin Journal: Cancer Med Date: 2020-03-12 Impact factor: 4.452
Authors: Karen Toledo-Stuardo; Carolina H Ribeiro; Andrea Canals; Marcela Morales; Valentina Gárate; Jose Rodríguez-Siza; Samantha Tello; Marco Bustamante; Ricardo Armisen; Douglas J Matthies; Gerald Zapata-Torres; Patricio González-Hormazabal; María Carmen Molina Journal: Front Immunol Date: 2021-03-31 Impact factor: 7.561